Valuation: Valneva SE Pref.

Market Cap 423M 483M 390M 365M 685M 45.54B 699M 4.69B 1.81B 22.51B 1.81B 1.77B 78.05B P/E 2026 *
-6.08x
P/E 2027 * 5.87x
Enterprise Value 551M 629M 508M 476M 892M 59.31B 911M 6.11B 2.36B 29.31B 2.36B 2.31B 102B EV / Sales 2026 *
3.63x
EV / Sales 2027 * 1.64x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Valneva SE Pref.

Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 483M
+0.47%+7.39%-4.88%+2.75% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-0.90%+7.69%+13.10%+20.99% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +0.65%+9.14%+77.69%+112.63% 25.57B
Weighted average by Cap. +0.84%+8.71%+88.90%+131.31%

Financials

2026 *2027 *
Net sales 152M 173M 140M 131M 246M 16.33B 251M 1.68B 651M 8.07B 650M 636M 27.99B 294M 335M 271M 254M 476M 31.63B 486M 3.26B 1.26B 15.63B 1.26B 1.23B 54.21B
Net income -66.01M -75.29M -60.85M -56.97M -107M -7.1B -109M -731M -283M -3.51B -283M -277M -12.17B 70.5M 80.41M 64.99M 60.84M 114M 7.59B 116M 781M 302M 3.75B 302M 295M 13B
Net Debt 128M 146M 118M 110M 207M 13.77B 211M 1.42B 549M 6.81B 548M 536M 23.6B 60.02M 68.45M 55.32M 51.79M 97.12M 6.46B 99.14M 665M 257M 3.19B 257M 251M 11.07B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.232EUR
Average target price
5.233EUR
Spread / Average Target
+134.47%

Quarterly revenue - Rate of surprise